Cardio Diagnostics Holdings Inc (Nasdaq: CDIO) and Houston Concierge Medicine have joined forces to provide a revolutionary new test for coronary heart disease. Cardio Diagnostics’ Epi+Gen CHD test combines the latest in epigenetics, genetics, high-throughput computing, and AI to identify those at risk, and is now available to Houston Concierge Medicine’s Executive Health Program patients.
Employers are recognizing the great value of preventive care and wellness for their executives, which is why executive physicals are becoming more commonplace. These physicals grant employers the unique opportunity to encourage healthy habits among their key employees and identify and address any potential health risks before they become serious. In the long run, this helps to reduce medical costs and absenteeism, making executive physicals an invaluable employee benefit.
“I am thrilled to announce a new partnership between Dr. Burzynski and Houston Concierge Medicine. We are both dedicated to providing personalized and precise healthcare for our patients. Through this partnership, we will be introducing the Epi+Gen CHD, an epigenomics-driven health decision-making tool that has been proven to be effective in providing precise and personalized care. We believe that this partnership will help us improve the health and well-being of our patients. We look forward to working together to provide the best care possible.”
“At Houston Concierge Medicine, we understand the importance of providing our patients with top-notch diagnostic solutions. That’s why we are excited to partner with Cardio Diagnostics and introduce Epi+Gen CHD, a non-invasive, objective test to determine risk for heart disease – a critical issue for many of our clients in high-pressure, fast-paced environments. We are proud to offer this cutting-edge service to our valued patients.”
About Houston Concierge Medicine
Houston Concierge Medicine & Wellness Center is a premier medical practice in Houston, dedicated to providing executives and health-conscious individuals with top-of-the-line diagnostic and treatment services to ensure optimum health and wellbeing. Our team of experienced professionals strive to provide the highest quality of care and personalized attention to each and every patient.
About Cardio Diagnostics
Cardio Diagnostics is revolutionizing the way cardiovascular disease is prevented, detected, and treated. By developing and commercializing its proprietary Artificial Intelligence-driven Integrated Genetic-Epigenetic EngineTM, Cardio Diagnostics is making the early detection and prevention of cardiovascular disease more personalized, precise, and accessible. This cutting-edge company is set to become one of the leading medical technology companies in the fight against cardiovascular disease.
Cardio Technologies, Inc. is pleased to announce the launch of its Epi+Gen CHD™ test, a potential game-changer for the diagnosis of cardiovascular diseases. However, there are risks and uncertainties associated with this launch, and success is not guaranteed. Factors such as the acceptance and adoption by patients, healthcare professionals, and other key channels, the impact of COVID-19, the ability to obtain and maintain regulatory approval, competition, pricing and reimbursement, and the size and growth potential of the market all have the potential to affect the Company’s success. We caution readers not to place undue reliance upon any forward-looking statements. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements.